Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts

Journal of Pharmacological Sciences

Volumn 104, Issue 2, 2007, Pages 167-175

  Kitagawa, Yutaka ^a   Tamura, Yamato ^a   Shimizu, Juichiro ^a   Nakajima Takenaka, Chikako ^a   Taniguchi, Shigeki ^a   Uesato, Shinichi ^b   Takaki, Miyako ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANSAI UNIVERSITY   (Japan)

Author keywords

Collagen; Conductance catheter; Histone deacetylase; Hypertrophy; Left ventricular volumetry

Indexed keywords

COLLAGEN; HISTONE DEACETYLASE INHIBITOR; ISOPRENALINE; K 183; N (2 AMINOPHENYL) 4 [[BENZYL(2 HYDROXYETHYL)AMINO]METHYL]BENZAMIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLLAGEN SYNTHESIS; DRUG INFUSION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE WORK; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; OSMOTIC MINIPUMP; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 34250859402     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0070091     Document Type: Article

References (36)

1. Tachibana H, Takaki M, Lee S, Ito H, Yamaguchi H, Suga H. New mechanoenergetic evaluation of left ventricular contractility in in situ rat hearts. Am J Physiol Heart Circ Physiol. 1997;272:H2671-H2678.
2. Lee S, Ohga Y, Tachibana H, Syuu Y, Ito H, Harada M, et al. Effects of myosin isozyme shift on curvilinearity of the left ventricular end-systolic pressure-volume relation of In situ rat hearts. Jpn J Physiol. 1998;48:445-455.
3. Kishi T, Nakahashi K, Ito H, Taniguchi S, Takaki M. Effects of milrinone on left ventricular end-systolic pressure-volume relationship of rat hearts in situ. Clin Exp Pharmacol Physiol. 2001;28:737-742.
4. Kitagawa Y, Yamashita D, Ito H, Takaki M. The reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts. Am J Physiol Heart Circ Physiol. 2004;287:H277-H285.
5. Kuzumoto N, Kitagawa Y, Uemura K, Ueyama T, Yoshida K, et al. A brief regional ischemic-reperfusion enhances propofol-induced depression in left ventricular function of in situ rat hearts. Anesthesiology. 2004;101:879-887.
6. Takaki M. Left ventricular mechanoenergetics in small animals. Jpn J Physiol. 2004;54:175-207.
7. Nakahashi K, Kitagawa Y, Ito H, Kuzumoto N, Furuya H, Takaki M. Positive inotropic effect of nicorandil in in situ adult rats. J Anesth. 2005;19:45-53.
8. Abe T, Ohga Y, Tabayashi N, Kobayashi S, Sakata S, Misawa H, et al. Left ventricular diastolic dysfunction in type II diabetes mellitus model rats. Am J Physiol Heart Circ Physiol. 2002;282:H138-H148.
9. Ohga Y, Sakata S, Takenaka C, Abe T, Tsuji T, Taniguchi S, et al. Cardiac dysfunction in terms of left ventricular mechanical work and energetics in hypothyroid rats. Am J Physiol Heart Circ Physiol. 2002;283:H631-H641.
10. 2+ exchange inhibition protects the rat heart from ischemic-reperfusion injury by blocking energy-wasting processes. Am J Physiol Heart Circ Physiol. 2005;288:H1699-H1707.
11. Yoshikawa Y, Hagihara H, Ohga Y, Nakajima-Takenaka C, Murata K, Taniguchi S, et al. Calpain inhibitor-1 protects the rat heart from ischemic-reperfusion injury: analysis by mechanical work and energetics. Am J Physiol Heart Circ Physiol. 2005;288:H1690-H1698.
12. Stanton HC, Brenner G, Mayfield ED Jr. Studies on isoproterenol-induced cardiomegaly in rats. Am Heart J. 1969;77:72-80.
13. Zierhut W, Zimmer HG. Significance of myocardial alpha- and beta-adrenoceptors in catecholamine-induced cardiac hypertrophy. Circ Res. 1989;65:1417-1425.
14. Boluyt MO, Long X, Eschenhagen T, Mende U, Schmitz W, Crow MT, et al. Isoproterenol infusion induces alterations in expression of hypertrophy- associated genes in rat heart. Am J Physiol Heart Circ Physiol. 1995;269:H638-H647.
15. Nagano M, Higaki J, Nakamura F, Higashimori K, Nagano N, Mikami H, et al. Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. Hypertension. 1992;19:708-712.
16. Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science. 1998;281:1690-1693.
17. Sugden PH. Signaling in myocardial hypertrophy: life after calcineurin? Circ Res. 1999;84:633-646.
18. Antos CL, Frey N, Marx SO, Reiken S, Gaburjakova M, Richardson JA, et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res. 2001;89:938-940.
19. Leenen FH, White R, Yuan B. Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. Am J Physiol Heart Circ Physiol. 2001;281:H2410-H2416.
20. Morisco C, Zebrowski DC, Vatner DE, Vatner SF, Sadoshima J. Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart. Mol Cell Cardiol. 2001;33:561-573.
21. Metzger JM. HDAC lightens a heavy heart. Nat Med. 2002;8:1078-1079.
22. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res. 2004;95:971-980.
23. Gray SG, Ekström TJ. The human histone deacetylase family. Exp Cell Res. 2001;262:75-83.
24. Zhang CL, Mckinsey TA, Chang S, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell. 2002;110:479-488.
25. Nagaoka Y, Maeda T, Kawai Y, Nakashima D, Oikawa T, Shimoke K, et al. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives. Eur J Med Chem. 2006;41:697-708.
26. Hamamori Y, Schneider MD. HATs off to Hop: recruitment of a class I histone deacetylase incriminates a novel transcriptional pathway that opposes cardiac hypertrophy. J Clin Invest. 2003;112:824-826.
27. Kook H, Lepore JJ, Gitler AD, Lu MM, Yung WW-M, Mackoy J, et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J Clin Invest. 2003;112:863-871.
28. Harrison BC, Roberts CR, Hood DB, Sweeney M, Gould JM, Bush EW, et al. The CRM1 nuclear export receptor controls pathological cardiac gene expression. Mol Cell Biol. 2004;24:10636-10649.
29. Mckinsey TA, Olson EN. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 2004;20:206-213.
30. Davis FJ, Pillai JB, Gupta M, Gupta MP. Concurrent opposite effects of trichostatin-A, an inhibitor of histone deacetylases, on the expression of α-MHC and cardiac tubulins: implication for gain in cardiac muscle contractility. Am J Physiol Heart Circ Physiol. 2005;288:H1477-H1490.
31. Baan J, Aouw Jong TT, Kerkhof PLM, Moene RJ, Van Dijk AD, Van Der Velde ET, et al. Continuous stroke volume and cardiac output from intra-ventricular dimensions obtained with impedance catheter. Cardiovasc Res. 1981;15:328-334.
32. Baan J, Van Der Velde ET, De Bruin HG, Smeenk GJ, Koops J, Van Dijk AD, et al. Continuous measurement of left ventricular volume in animals and humans by conductance catheter. Circulation 1984;70:812-823.
33. Ito H, Takaki M, Yamaguchi H, Tachibana H, Suga H. Left ventricular volumetric conductance catheter for rats. Am J Physiol Heart Circ Physiol. 1996;270:H1509-H1514.
34. Suga H, Hayashi T, Suehiro S, Hisano R, Shirahata M, Ninomiya I. Equal oxygen consumption rates of isovolumic and ejecting contractions with equal systolic pressure-volume areas in canine left ventricle. Circ Res. 1981;49:1082-1091.
35. Sakata S, Ohga Y, Abe T, Tabayashi N, Kobayashi S, Tsuji T, et al. No dependency of a new index for oxygen cost of left ventricular contractility on heart rates in the blood-perfused excised rat hearts. Jpn J Physiol. 2001;51:177-185.
36. Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in virto by trichostatin A. J Biol Chem. 1990;265:17174-17179.